Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01071291 | Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069) | PHASE1 | COMPLETED | 37 | — | — | Feb 1, 2010 | Sep 1, 2010 | Oct 12, 2015 | - | — |
| NCT01104519 | A Study of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity (0000-093) | PHASE1 | COMPLETED | 12 | — | — | Mar 1, 2008 | Jul 1, 2008 | Jul 30, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | Arm A will receive a Niaspan treatment in Period 1 and Placebo treatment in Period 2 |
| Arm B | EXPERIMENTAL | Arm B will receive a Placebo treatment in Period 1 and Niaspan treatment in Period 2 |
| 1 | EXPERIMENTAL | Niaspan - Placebo |
| 2 | EXPERIMENTAL | Placebo - Niaspan |
| Name | Type | Description |
|---|---|---|
| Niaspan | DRUG | Niaspan™ |
| Comparator: Placebo | DRUG | Placebo |
Inclusion Criteria: * Healthy Male Subjects Exclusion Criteria : * Subject has a history of stroke, chronic seizures, or major neurological disorder * Subject has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respira...